Search for a trial

A prospective evaluation of pancreatic cyst surveillance, based on the consensus statement, formulated by the European study group on cystic tumours of the pancreas

First, to establish the yield of the currently propagated pancreatic cyst surveillance program, and second, to identify possible alternative surveillance strategies, which might be more (cost) effective.

Clinical Performance Study Plan (CPSP) for the use of GenDx CDx Tedopi for subject enrollment on to the OSE Immunotherapeutics Phase 3 trial (OSE2101C302) of OSE2101 versus docetaxel in HLA-A*02 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ARTEMIA)

This clinical performance study/clinical investigation will evaluate the safety and effectiveness of GenDx CDx Tedopi in identifying HLA-A*02 status in metastatic NSCLC subjects who may be eligible for treatment with OSE2101.